Updates on the pathophysiology of dermal sclerosis

References

• Yamamoto T. Scleroderma – pathophysiology. Eur. J. Dermatol. 19(1), 14–24 (2009).
   PubMed Web of Science ®Google Scholar
• Beyer C, Schett G, Distler O, Distler JH. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum. 62(10), 2831–2844 (2010).
   PubMed Web of Science ®Google Scholar
• Radstake TR, van Bon L, Broen J et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression. PLoS ONE 4(6), e5981 (2009).
   Web of Science ®Google Scholar
• Slobodin G, Ahmad MS, Rosner I et al. Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell. Immunol. 261(2), 77–80 (2010).
   PubMed Web of Science ®Google Scholar
• Antiga E, Quaglino P, Bellandi S et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br. J. Dermatol. 162(5), 1056–1063 (2010).
   PubMed Web of Science ®Google Scholar
• Higashi-Kuwata N, Jinnin M, Makino T et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res. Ther. 12(4), R128 (2010).
   Web of Science ®Google Scholar
• Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451–483 (2009).
   PubMed Web of Science ®Google Scholar
• Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. 50(6), 1918–1927 (2004).
   PubMed Web of Science ®Google Scholar
• Smith V, Van Praet JT, Vandooren B et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann. Rheum. Dis. 69(1), 193–197 (2010).
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN, Tsamandas AC et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 49(2), 271–280 (2010).
   PubMed Web of Science ®Google Scholar
• Bosello S, De Santis M, Lama G et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res. Ther. 12(2), R54 (2010).
   PubMed Web of Science ®Google Scholar
• Daoussis D, Tsamandas AC, Liossis SN et al. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res. Ther. 14(3), R145 (2012).
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Hamaguchi Y, Yanaba K et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am. J. Pathol. 169(3), 954–966 (2006).
   PubMed Web of Science ®Google Scholar
• Broen JC, Coenen MJ, Radstake TR. Genetics of systemic sclerosis: an update. Curr. Rheumatol. Rep. 14(1), 11–21 (2012).
   PubMed Web of Science ®Google Scholar
• Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J. Invest. Dermatol. 110(1), 47–51 (1998).
   PubMed Web of Science ®Google Scholar
• Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum. 44(3), 731–734 (2001).
   PubMedGoogle Scholar
• Dong C, Zhu S, Wang T et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc. Natl Acad. Sci. USA 99(6), 3908–3913 (2002).
   PubMed Web of Science ®Google Scholar
• Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J. Clin. Invest. 113(2), 253–264 (2004).
   PubMed Web of Science ®Google Scholar
• Morris E, Chrobak I, Bujor A et al. Endoglin promotes TGF-b/Smad1 signaling in scleroderma fibroblasts. J. Cell. Physiol. 226(12), 3340–3348 (2011).
   PubMed Web of Science ®Google Scholar
• Varga J, Whitfield ML. Transforming growth factor-β in systemic sclerosis (scleroderma). Front. Biosci. (Schol. Ed.) 1, 226–235 (2009).
   PubMedGoogle Scholar
• Samuel GH, Bujor AM, Nakerakanti SS, Hant FN, Trojanowska M. Autocrine transforming growth factor b signaling regulates extracellular signal-regulated kinase ½ phosphorylation via modulation of protein phosphatase 2A expression in scleroderma fibroblasts. Fibrogenesis Tissue Repair 3, 25 (2010).
   PubMedGoogle Scholar
• Bhattacharyya S, Chen SJ, Wu M et al. Smad-independent transforming growth factor-β regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am. J. Pathol. 173(4), 1085–1099 (2008).
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Sargent JL, Du P et al. Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PLoS ONE 6(9), e23082 (2011).
   Google Scholar
• Fang F, Ooka K, Bhattacharyya S et al. The early growth response gene EGR2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-b that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am. J. Pathol. 178(5), 2077–2090 (2011).
   PubMedGoogle Scholar
• Holmes AM, Ponticos M, Shi-Wen X, Denton CP, Abraham DJ. Elevated CCN2 expression in scleroderma: a putative role for the TGFb accessory receptors TGFbRIII and endoglin. J. Cell Commun. Signal. 5(3), 173–177 (2011).
   PubMedGoogle Scholar
• Sonnylal S, Shi-Wen X, Leoni P et al. Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum. 62(5), 1523–1532 (2010).
   PubMed Web of Science ®Google Scholar
• Holmes A, Abraham DJ, Chen Y et al. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J. Biol. Chem. 278(43), 41728–41733 (2003).
   PubMedGoogle Scholar
• Sato S, Nagaoka T, Hasegawa M et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J. Rheumatol. 27(1), 149–154 (2000).
   PubMed Web of Science ®Google Scholar
• Ishibuchi H, Abe M, Yokoyama Y, Ishikawa O. Induction of matrix metalloproteinase-1 by small interfering RNA targeting connective tissue growth factor in dermal fibroblasts from patients with systemic sclerosis. Exp. Dermatol. 19(8), 111–116 (2010).
   Google Scholar
• Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int. Arch. Allergy Immunol. 140(4), 345–356 (2006).
   PubMedGoogle Scholar
• Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J. Biol. Chem. 271(30), 17779–17784 (1996).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1α loop. J. Immunol. 164(12), 6174–6179 (2000).
   PubMed Web of Science ®Google Scholar
• Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum. 44(6), 1382–1386 (2001).
   PubMedGoogle Scholar
• Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin. Exp. Immunol. 117(1), 159–165 (1999).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Eckes B, Hartmann K, Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J. Dermatol. Sci. 26(2), 133–139 (2001).
   PubMed Web of Science ®Google Scholar
• Distler O, Pap T, Kowal-Bielecka O et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum. 44(11), 2665–2678 (2001).
   PubMedGoogle Scholar
• Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur. J. Immunol. 31(10), 2936–2941 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu Z, Ma B, Zheng T et al. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J. Immunol. 168(6), 2953–2962 (2002).
   PubMed Web of Science ®Google Scholar
• Greenblatt MB, Sargent JL, Farina G et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am. J. Pathol. 180(3), 1080–1094 (2012).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J. Invest. Dermatol. 121(3), 510–516 (2003).
   PubMed Web of Science ®Google Scholar
• Chujo S, Shirasaki F, Kondo-Miyazaki M, Ikawa Y, Takehara K. Role of connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein-1 in skin fibrosis. J. Cell. Physiol. 220(1), 189–195 (2009).
   PubMed Web of Science ®Google Scholar
• Carulli MT, Ong VH, Ponticos M et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum. 52(12), 3772–3782 (2005).
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Pathogenic role of CCL2/MCP-1 in scleroderma. Front. Biosci. 13, 2686–2695 (2008).
   PubMedGoogle Scholar
• Distler JH, Akhmetshina A, Schett G, Distler O. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford). 48(2), 98–103 (2009).
   PubMed Web of Science ®Google Scholar
• Kitaba S, Murota H, Terao M et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am. J. Pathol. 180(1), 165–176 (2012).
   PubMed Web of Science ®Google Scholar
• Shima Y, Kuwahara Y, Murota H et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 49(12), 2408–2412 (2010).
   PubMed Web of Science ®Google Scholar
• Le Huu D, Matsushita T, Jin G et al. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J. Invest. Dermatol. 132(12), 2752–2761(2012).
   PubMed Web of Science ®Google Scholar
• Van Praet JT, Smith V, Haspeslagh M, Degryse N, Elewaut D, De Keyser F. Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study. Arthritis Res. Ther. 13(1), R35 (2011).
   PubMed Web of Science ®Google Scholar
• Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med. 354(25), 2667–2676 (2006).
   PubMed Web of Science ®Google Scholar
• Motegi S, Garfield S, Feng X, Sárdy M, Udey MC. Potentiation of platelet-derived growth factor receptor-b signaling mediated by integrin-associated MFG-E8. Arterioscler. Thromb. Vasc. Biol. 31(11), 2653–2664 (2011).
   PubMedGoogle Scholar
• Maurer B, Busch N, Jüngel A et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 120(23), 2367–2376 (2009).
   PubMed Web of Science ®Google Scholar
• Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 364(9434), 603–610 (2004).
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Okazaki Y, Seta N et al. Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. Arthritis Res. Ther. 12(6), R205 (2010).
   Web of Science ®Google Scholar
• Horstmeyer A, Licht C, Scherr G, Eckes B, Krieg T. Signalling and regulation of collagen I synthesis by ET-1 and TGF-β1. FEBS J. 272(24), 6297–6309 (2005).
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Denton CP, Dashwood MR et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J. Invest. Dermatol. 116(3), 417–425 (2001).
   PubMed Web of Science ®Google Scholar
• Shephard P, Hinz B, Smola-Hess S, Meister JJ, Krieg T, Smola H. Dissecting the roles of endothelin, TGF-β and GM-CSF on myofibroblast differentiation by keratinocytes. Thromb. Haemost. 92(2), 262–274 (2004).
   PubMedGoogle Scholar
• Vancheeswaran R, Magoulas T, Efrat G et al. Circulating endothelin-1 levels in systemic sclerosis subsets – a marker of fibrosis or vascular dysfunction? J. Rheumatol. 21(10), 1838–1844 (1994).
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Chen Y, Denton CP et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol. Biol. Cell 15(6), 2707–2719 (2004).
   PubMed Web of Science ®Google Scholar
• Hirata Y, Emori T, Eguchi S et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J. Clin. Invest. 91(4), 1367–1373 (1993).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J. Rheumatol. 25(2), 314–317 (1998).
   PubMed Web of Science ®Google Scholar
• Beyer C, Schett G, Gay S, Distler O, Distler JH. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res. Ther. 11(2), 220 (2009).
   PubMedGoogle Scholar
• Kubo M, Czuwara-Ladykowska J, Moussa O et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am. J. Pathol. 163(2), 571–581 (2003).
   PubMedGoogle Scholar
• Asano Y, Stawski L, Hant F et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am. J. Pathol. 176(4), 1983–1998 (2010).
   PubMed Web of Science ®Google Scholar
• Bujor AM, Asano Y, Haines P, Lafyatis R, Trojanowska M. The c-Abl tyrosine kinase controls protein kinase Cd-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum. 63(6), 1729–1737 (2011).
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Wu M, Livingston CK et al. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res. Ther. 13(1), R3 (2011).
   PubMed Web of Science ®Google Scholar
• Gailit J, Marchese MJ, Kew RR, Gruber BL. The differentiation and function of myofibroblasts is regulated by mast cell mediators. J. Invest. Dermatol. 117(5), 1113–1119 (2001).
   PubMed Web of Science ®Google Scholar
• Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int. J. Biochem. Cell Biol. 36(4), 598–606 (2004).
   PubMed Web of Science ®Google Scholar
• Katebi M, Fernandez P, Chan ES, Cronstein BN. Adenosine A2A receptor blockade or deletion diminishes fibrocyte accumulation in the skin in a murine model of scleroderma, bleomycin-induced fibrosis. Inflammation 31(5), 299–303 (2008).
   PubMed Web of Science ®Google Scholar
• Maurer B, Stanczyk J, Jüngel A et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62(6), 1733–1743 (2010).
   PubMed Web of Science ®Google Scholar
• Honda N, Jinnin M, Kajihara I et al. TGF-b-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J. Immunol. 188(7), 3323–3331 (2012).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Tokura Y. Expression of SNAI1 and TWIST1 in the eccrine glands of patients with systemic sclerosis: possible involvement of epithelial-mesenchymal transition in the pathogenesis. Br. J. Dermatol. 164(1), 204–205 (2011).
   PubMedGoogle Scholar
• Aden N, Nuttall A, Shiwen X et al. Epithelial cells promote fibroblast activation via IL-1α in systemic sclerosis. J. Invest. Dermatol. 130(9), 2191–2200 (2010).
   PubMed Web of Science ®Google Scholar
• Palumbo K, Zerr P, Tomcik M et al. The transcription factor JunD mediates transforming growth factor {β}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann. Rheum. Dis. 70(7), 1320–1326 (2011).
   PubMed Web of Science ®Google Scholar
• Avouac J, Palumbo K, Tomcik M et al. Inhibition of activator protein 1 signaling abrogates transforming growth factor b-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum. 64(5), 1642–1652 (2012).
   PubMed Web of Science ®Google Scholar
• Beyer C, Schramm A, Akhmetshina A et al. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann. Rheum. Dis. 71(5), 761–767 (2012).
   PubMed Web of Science ®Google Scholar
• Bergmann C, Akhmetshina A, Dees C et al. Inhibition of glycogen synthase kinase 3ß induces dermal fibrosis by activation of the canonical Wnt pathway. Ann. Rheum. Dis. 70(12), 2191–2198 (2011).
   PubMed Web of Science ®Google Scholar
• Jelaska A, Korn JH. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum. 43(10), 2230–2239 (2000).
   PubMed Web of Science ®Google Scholar
• Santiago B, Galindo M, Rivero M, Pablos JL. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum. 44(7), 1667–1676 (2001).
   PubMed Web of Science ®Google Scholar
• Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J. Clin. Invest. 98(3), 785–792 (1996).
   PubMed Web of Science ®Google Scholar
• Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor β(1). Am. J. Respir. Cell Mol. Biol. 21(6), 658–665 (1999).
   PubMed Web of Science ®Google Scholar
• Laplante P, Raymond MA, Gagnon G et al. Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J. Immunol. 174(9), 5740–5749 (2005).
   PubMed Web of Science ®Google Scholar
• Barnes TC, Spiller DG, Anderson ME, Edwards SW, Moots RJ. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis? Ann. Rheum. Dis. 70(2), 366–372 (2011).
   PubMedGoogle Scholar
• Wetzig T, Petri JB, Mittag M, Haustein UF. Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis. Arch. Dermatol. Res. 290(4), 187–190 (1998).
   PubMedGoogle Scholar
• Stummvoll GH, Aringer M, Smolen JS et al. Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology (Oxford) 39(12), 1341–1350 (2000).
   PubMed Web of Science ®Google Scholar
• Bianchi T, Bardazzi F, Patrizi A. Soluble Fas levels in patients with systemic sclerosis. Arch. Dermatol. Res. 292(10), 522–523 (2000).
   PubMedGoogle Scholar
• Ates A, Kinikli G, Turgay M, Duman M. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin. Rheumatol. 23(5), 421–425 (2004).
   PubMedGoogle Scholar
• Kessel A, Rosner I, Rozenbaum M et al. Increased CD8+ T-cell apoptosis in scleroderma is associated with low levels of NF-κB. J. Clin. Immunol. 24(1), 30–36 (2004).
   PubMed Web of Science ®Google Scholar
• Jun JB, Kuechle M, Min J et al. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J. Invest. Dermatol. 124(2), 298–303 (2005).
   PubMedGoogle Scholar
• Yamamoto T. Autoimmune mechanisms of scleroderma and a role of oxidative stress. Self Nonself. 2(1), 4–10 (2011).
   PubMedGoogle Scholar
• Avouac J, Borderie D, Ekindjian OG, Kahan A, Allanore Y. High DNA oxidative damage in systemic sclerosis. J. Rheumatol. 37(12), 2540–2547 (2010).
   PubMedGoogle Scholar
• Murrell GA, Francis MJ, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem. J. 265(3), 659–665 (1990).
   PubMed Web of Science ®Google Scholar
• Falanga V, Martin TA, Takagi H et al. Low oxygen tension increases mRNA levels of α 1 (I) procollagen in human dermal fibroblasts. J. Cell. Physiol. 157(2), 408–412 (1993).
   PubMed Web of Science ®Google Scholar
• Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J. Exp. Med. 185(1), 71–79 (1997).
   PubMed Web of Science ®Google Scholar
• Sambo P, Baroni SS, Luchetti M et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 44(11), 2653–2664 (2001).
   PubMed Web of Science ®Google Scholar
• Galindo M, Santiago B, Alcami J, Rivero M, Martín-Serrano J, Pablos JL. Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clin. Exp. Immunol. 123(1), 36–41 (2001).
   PubMed Web of Science ®Google Scholar
• Servettaz A, Goulvestre C, Kavian N et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J. Immunol. 182(9), 5855–5864 (2009).
   PubMed Web of Science ®Google Scholar
• Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Selective upregulation of platelet-derived growth factor α receptors by transforming growth factor β in scleroderma fibroblasts. J. Exp. Med. 175(5), 1227–1234 (1992).
   PubMed Web of Science ®Google Scholar
• Klareskog L, Gustafsson R, Scheynius A, Hällgren R. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum. 33(10), 1534–1541 (1990).
   PubMedGoogle Scholar
• Xue-yi Z, Jian-Zhong Z, Ping T, Sheng-Qing M. Expression of platelet-derived growth factor B-chain and platelet-derived growth factor β-receptor in fibroblasts of scleroderma. J. Dermatol. Sci. 18, 90–97 (1998).
   PubMedGoogle Scholar
• Tsou PS, Talia NN, Pinney AJ et al. Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts. Arthritis Rheum. 64(6), 1978–1989 (2012).
   PubMedGoogle Scholar
• Classen JF, Henrohn D, Rorsman F et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum. 60(4), 1137–1144 (2009).
   PubMed Web of Science ®Google Scholar
• Avouac J, Fürnrohr BG, Tomcik M et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum. 63(3), 800–809 (2011).
   PubMed Web of Science ®Google Scholar
• Burt RK, Shah SJ, Dill K et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised Phase 2 trial. Lancet 378(9790), 498–506 (2011).
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Animal model of systemic sclerosis. J. Dermatol. 37(1), 26–41 (2010).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Takagawa S, Katayama I, Nishioka K. Anti-sclerotic effect of transforming growth factor-β antibody in a mouse model of bleomycin-induced scleroderma. Clin. Immunol. 92(1), 6–13 (1999).
   PubMed Web of Science ®Google Scholar
• Santiago B, Gutierrez-Cañas I, Dotor J et al. Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis. J. Invest. Dermatol. 125(3), 450–455 (2005).
   PubMed Web of Science ®Google Scholar
• Nakamura-Wakatsuki T, Oyama N, Yamamoto T. Local injection of latency-associated peptide, a linker propeptide specific for active form of transforming growth factor-β1, inhibits dermal sclerosis in bleomycin-induced murine scleroderma. Exp. Dermatol. 21(3), 189–194 (2012).
   PubMed Web of Science ®Google Scholar
• Wu MH, Yokozeki H, Takagawa S et al. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Ther. 11(2), 170–180 (2004).
   PubMedGoogle Scholar
• Yamamoto T, Takagawa S, Katayama I, Mizushima Y, Nishioka K. Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: implications for the treatment of systemic sclerosis. J. Invest. Dermatol. 113(5), 843–847 (1999).
   PubMed Web of Science ®Google Scholar
• Kokot A, Sindrilaru A, Schiller M et al. α-Melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum. 60(2), 592–603 (2009).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Takagawa S, Kuroda M, Nishioka K. Effect of interferon-γ on experimental scleroderma induced by bleomycin. Arch. Dermatol. Res. 292(7), 362–365 (2000).
   PubMedGoogle Scholar
• Kimura M, Kawahito Y, Hamaguchi M et al. SKL-2841, a dual antagonist of MCP-1 and MIP-1 β, prevents bleomycin-induced skin sclerosis in mice. Biomed. Pharmacother. 61(4), 222–228 (2007).
   PubMedGoogle Scholar
• Kajii M, Suzuki C, Kashihara J et al. Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma. Clin. Exp. Immunol. 163(2), 235–241 (2011).
   PubMed Web of Science ®Google Scholar
• Distler JH, Jüngel A, Huber LC et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 56(1), 311–322 (2007).
   PubMed Web of Science ®Google Scholar
• Koca SS, Isik A, Ozercan IH, Ustundag B, Evren B, Metin K. Effectiveness of etanercept in bleomycin-induced experimental scleroderma. Rheumatology (Oxford) 47(2), 172–175 (2008).
   PubMed Web of Science ®Google Scholar
• Terao M, Murota H, Kitaba S, Katayama I. Tumor necrosis factor-α processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma. Exp. Dermatol. 19(1), 38–43 (2010).
   PubMedGoogle Scholar
• Akhmetshina A, Dees C, Pileckyte M et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22(7), 2214–2222 (2008).
   PubMed Web of Science ®Google Scholar
• Kawai M, Masuda A, Kuwana M. A CD40-CD154 interaction in tissue fibrosis. Arthritis Rheum. 58(11), 3562–3573 (2008).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Nishioka K. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J. Invest. Dermatol. 122(1), 44–50 (2004).
   PubMed Web of Science ®Google Scholar
• Yoshizaki A, Yanaba K, Yoshizaki A et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum. 62(8), 2476–2487 (2010).
   PubMedGoogle Scholar
• Ikeda H, Sunazuka T, Suzuki H et al. EM703, the new derivative of erythromycin, inhibits transcription of type I collagen in normal and scleroderma fibroblasts. J. Dermatol. Sci. 49(3), 195–205 (2008).
   PubMed Web of Science ®Google Scholar
• Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-γ. Am. J. Pathol. 174(2), 519–533 (2009).
   PubMed Web of Science ®Google Scholar
• Chan ES, Fernandez P, Merchant AA et al. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 54(8), 2632–2642 (2006).
   PubMed Web of Science ®Google Scholar
• Balistreri E, Garcia-Gonzalez E, Selvi E et al. The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model. Ann. Rheum. Dis. 70(4), 695–699 (2011).
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Matsushita Y, Horikawa M et al. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis. Arthritis Rheum. 60(11), 3465–3475 (2009).
   PubMed Web of Science ®Google Scholar
• Avouac J, Palumbo K, Tomcik M et al. Inhibition of AP-1 signaling abrogates TGF-β mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum. 64(5), 1642–1652 (2011).
   Google Scholar
• Dees C, Zerr P, Tomcik M et al. Inhibition of notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum. 63(5), 1396–1404 (2011).
   PubMed Web of Science ®Google Scholar
• Ozgen M, Koca SS, Dagli AF, Gundogdu B, Ustundag B, Isik A. Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma. Clin. Exp. Dermatol. 37(1), 48–54 (2012).
   PubMedGoogle Scholar
• Koca SS, Ozgen M, Dagli F et al. Proteasome inhibition prevents development of experimental dermal fibrosis. Inflammation 35(3), 810–817 (2011).
   Google Scholar